



PEAK-1_CC_Flyer_V1_31032026

PEAK-1 Study – Clear cell Renal Cell Carcinoma



Study Background

This clinical trial is investigating an experimental study drug (casdatifan) for people living with unresectable, locally advanced, or metastatic renal cell carcinoma with a primary clear cell component. The purpose of the study is to determine if the study drug extends the time before cancer progresses.

Clinical trials have complex eligibility criteria. We encourage you to speak to your primary doctor or medical oncologist if you are unsure.



About the study

Before joining the study, you will attend a screening visit. During this visit, the study team will review your medical history, do a physical exam, check your vital signs, run blood and urine tests, perform heart tests (like an ECG), and complete scans.

Once you start treatment, each treatment cycle lasts 28 days. In the first two cycles, you'll have visits on Day 1 and Day 15. From Cycle 3 onward, you'll have a visit on Day 1 of each cycle.

You'll also have scans every 8 weeks for the first 2 years, then every 12 weeks after that. These scans help track how your cancer is responding.



Eligibility

You may be eligible for this study if you meet the following criteria:

- Aged 18 and above
- Unresectable (cannot be surgically removed or fully removed/resected), locally advanced or metastatic renal cell carcinoma with a primary clear cell component.
- You have had previous immunotherapy treatment (anti-PD-1 or anti-PD-L1) but your cancer has progressed or has not responded to the treatment



Our patient support team is available to answer your questions about the PEAK 1 Study and help you understand your options.



Visit our website
canopycr.com.au

Find out more

For more information, please contact us on 1300 637 175 or email cancertrials@canopycr.com.au